Repros in the News

All Releases

View Summary Repros Announces New CEO

Feb 2, 2017

PDF 16.3 KB Add to Briefcase
View Summary FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids

Jan 30, 2017

PDF 16.5 KB Add to Briefcase
View Summary Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis

Dec 19, 2016

PDF 16.2 KB Add to Briefcase
View Summary Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids

Dec 12, 2016

PDF 19.1 KB Add to Briefcase
View Summary FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Dec 6, 2016

PDF 16.6 KB Add to Briefcase
View Summary Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

Nov 14, 2016

PDF 20.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Nov 8, 2016

PDF 24.5 KB Add to Briefcase
View Summary Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Oct 5, 2016

PDF 18.9 KB Add to Briefcase
View Summary FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

Sep 26, 2016

PDF 18.6 KB Add to Briefcase
View Summary Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Sep 12, 2016

PDF 19.6 KB Add to Briefcase
View Summary Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate to Severe Endometriosis

Sep 7, 2016

PDF 20.1 KB Add to Briefcase
View Summary Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Aug 15, 2016

PDF 20.8 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results

Aug 9, 2016

PDF 24.0 KB Add to Briefcase
View Summary Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Jun 1, 2016

PDF 20.6 KB Add to Briefcase
View Summary Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

May 18, 2016

PDF 20.1 KB Add to Briefcase
View Summary Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board

May 16, 2016

PDF 17.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

May 10, 2016

PDF 23.5 KB Add to Briefcase
View Summary Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Apr 12, 2016

PDF 20.0 KB Add to Briefcase
View Summary Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

Mar 15, 2016

PDF 17.2 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results

Mar 14, 2016

PDF 24.8 KB Add to Briefcase
Showing 1-20 of 186 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax